Effects of metformin on inflammation and short-term memory in streptozotocin-induced diabetic mice

Wilma Helena Oliveira1, Ana Karolina Nunes2, Maria Eduarda Rocha França1

  • 1Laboratório de Ultraestrutura, Centro de Pesquisas Aggeu Magalhães (CPqAM), PE, Brazil; Programa de Pós-graduação em Ciências Biológicas, Centro de Biociências, Universidade Federal de Pernambuco - UFPE, PE, Brazil.

Brain Research
|May 14, 2016
PubMed

Insights

Metformin treatment improved spatial memory in diabetic mice by reducing neuroinflammation and neuronal loss in the hippocampus. This study highlights metformin's potential for treating diabetic encephalopathy.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Endocrinology

Background:

  • Diabetic encephalopathy is characterized by cognitive deficits, neuroinflammation, and neuronal loss.
  • Streptozotocin-induced diabetes in mice serves as a model for studying diabetic complications.
  • Metformin is a widely used antidiabetic drug with potential neuroprotective effects.

Purpose of the Study:

  • To investigate the effects of metformin on short-term memory, glial cell activation, and neuroinflammation in experimental diabetic encephalopathy.
  • To analyze metformin's impact on hippocampal neuronal survival and related signaling pathways.

Main Methods:

  • Diabetes was induced in C57BL/6 mice using streptozotocin.
  • Diabetic mice were treated with metformin (100mg/kg and 200mg/kg) for 21 days.
  • Spatial memory was assessed using the T-maze test; neuroinflammation and neuronal survival markers were analyzed post-mortem.

Main Results:

  • Metformin treatment significantly improved spatial memory scores in diabetic mice.
  • Metformin reduced glial cell activation (GFAP, Iba-1), neuroinflammation (NF-kB, IL-1, VEGF), and neuronal loss (Fox-1, NeuN) in the hippocampus.
  • Enhanced levels of p-AMPK and eNOS were observed in metformin-treated diabetic mice.

Conclusions:

  • Metformin effectively mitigates neuroinflammation and neuronal loss in the hippocampus of diabetic mice.
  • Metformin treatment demonstrates potential therapeutic benefits for cognitive impairments associated with diabetic encephalopathy.